Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/30 11:42:11 am
411.075 DKK   -3.29%
09:15aNOVO NORDISK A/S : 3Q Net Profit Rose as Pandemic Disruption EaseD -- Earnings Review
DJ
08:49aNOVO NORDISK : Jefferies reaffirms its Sell rating
MD
08:46aNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : insulin production line launches in Iran

share with twitter share with LinkedIn share with facebook
09/01/2020 | 06:56pm EDT

Denmark’s Novo Nordisk has created an insulin production line in Iran, Mehr News Agency reported on August 31.

Iran’s pharmaceutical industry is known as one of the most localised in the world, with generic copies of major medicines often produced in the country.

The production line comes as the number of cases of type two diabetes continue to increase in the country. Around 5mn people among the Iranian population of around 83mn are now recognised as having either Type 1 or Type 2 diabetes, while 18% of the population is thought to be ‘pre-diabetic’.  

Novo Nordisk estimated that the investment project would cost €70mn.

The opening of a major foreign company production line could be taken as a nod and a wink to Iranian authorities that there may be light at the end of the tunnel if US President Donald Trump is turfed out of office by voters in November. His opponent Joe Biden is opposed to the crushing sanctions campaign being waged against Iran, a campaign that has meant swathes of foreign investors leaving Iran or giving up on it as an investment destination. Though very extensive, the sanctions regime does not directly target the food and humanitarian sectors of Iran.

Minister of Health Saeed Namaki inaugurated the plant's production line, in Alborz Province, west of Tehran, via video conference.

“Today we are witnessing the inauguration of one of the most important projects since the [1979 Islamic] revolution with the joint investment of Iran and Denmark,” Namaki said.

It is estimated that the production line will meet at least 30% of Iran’s insulin needs in the first phase, while it will target some additional regional needs in later phases.

Novo Nordisk will use the line to produce 25mn insulin pens in the first year and another 45mn pens in the second year.

The company has been operating on the Iranian market since 2005, with a representative office in Tehran and a presence in other cities.

 

 

 

 

©2020 bne IntelliNews , source Magazine


share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
09:15aNOVO NORDISK A/S : 3Q Net Profit Rose as Pandemic Disruption EaseD -- Earnings R..
DJ
08:49aNOVO NORDISK : Jefferies reaffirms its Sell rating
MD
08:46aNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
08:25aNOVO NORDISK : UBS sticks Neutral
MD
08:11aNOVO NORDISK : Goldman Sachs keeps its Buy rating
MD
05:04aNOVO NORDISK : 3Q Earnings Snapshot
AQ
03:22aNOVO NORDISK A/S : 3Q Net Profit Rose Amid Destocking, New Patients
DJ
03:19aNOVO NORDISK A/S : sales rise as more diabetics seek treatment
RE
02:31aNOVO NORDISK A/S : operating profit increased by 6% in Danish kroner and by 7% a..
AQ
02:31aNovo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at..
GL
More news
Financials
Sales 2020 128 B 20 043 M 20 043 M
Net income 2020 42 626 M 6 687 M 6 687 M
Net cash 2020 10 720 M 1 682 M 1 682 M
P/E ratio 2020 23,5x
Yield 2020 2,10%
Capitalization 988 B 155 B 155 B
EV / Sales 2020 7,65x
EV / Sales 2021 7,16x
Nbr of Employees 43 526
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 425,05 DKK
Spread / Highest target 28,2%
Spread / Average Target 5,31%
Spread / Lowest Target -28,2%
EPS Revisions
Managers
NameTitle
Lars Fruergaard JÝrgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S9.93%154 639
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518